EyePoint Pharmaceuticals (NASDAQ:EYPT) reported quarterly losses of $(0.64) per share which missed the analyst consensus estimate of $(0.51) by 25.49 percent. This is a 93.94 percent decrease over losses of $(0.33) per share from the same period last year. The company reported quarterly sales of $11.59 million which beat the analyst consensus estimate of $11.09 million by 4.47 percent. This is a 17.39 percent decrease over sales of $14.03 million the same period last year.